Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Company's lead drug candidate, APR-246, a first-in-class small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes, acute myeloid leukemia as well as additional hematologic and solid tumor malignancies. Aprea Therapeutics Inc. is based in Boston, Massachusetts....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 11 October 2025
2022-09-25 09:34:00 Sunday ET
Main reasons for share repurchases Temporary market undervaluation often induces corporate incumbents to initiate a share repurchase program to boost the
2017-12-01 06:30:00 Friday ET
Dr Kai-Fu Lee praises China as the next epicenter of artificial intelligence, smart data analysis, and robotic automation. With prior IT careers at Apple, M
2019-06-21 13:33:00 Friday ET
Amazon and Google face more intense antitrust scrutiny. In recent times, Justice Department and Federal Trade Commission have reached an internal agreement
2019-10-09 16:46:00 Wednesday ET
IMF chief economist Gita Gopinath indicates that competitive currency devaluation may be an ineffective solution to improving export prospects. In the form
2023-12-05 09:25:00 Tuesday ET
Better corporate ownership governance through worldwide convergence toward Berle-Means stock ownership dispersion Abstract We design a model
2023-05-31 11:27:00 Wednesday ET
What are the top global risks in trade, finance, and technology? In this macro report, we focus on the current global risks from inflation and growth con
Statement
Ratio
News